Anebulo Pharmaceuticals, Inc.
						ANEB
					
					
							
								$2.64
								$0.000.00%
								
							
						NASDAQ
					
				| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | 
| Total Other Revenue | -- | -- | -- | -- | -- | 
| Total Revenue | -- | -- | -- | -- | -- | 
| Cost of Revenue | -- | -- | -- | -- | -- | 
| Gross Profit | -- | -- | -- | -- | -- | 
| SG&A Expenses | 4.92M | 4.59M | 4.25M | 4.58M | 4.76M | 
| Depreciation & Amortization | -- | -- | -- | -- | -- | 
| Other Operating Expenses | -- | -- | -- | -- | -- | 
| Total Operating Expenses | 9.22M | 8.23M | 8.01M | 8.18M | 8.31M | 
| Operating Income | -9.22M | -8.23M | -8.01M | -8.18M | -8.31M | 
| Income Before Tax | -8.48M | -7.69M | -7.67M | -7.92M | -8.20M | 
| Income Tax Expenses | -- | -- | -- | -- | -- | 
| Earnings from Continuing Operations | -8.48 | -7.69 | -7.67 | -7.92 | -8.20 | 
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- | 
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- | 
| Minority Interest in Earnings | -- | -- | -- | -- | -- | 
| Net Income | -8.48M | -7.69M | -7.67M | -7.92M | -8.20M | 
| EBIT | -9.22M | -8.23M | -8.01M | -8.18M | -8.31M | 
| EBITDA | -- | -- | -- | -- | -- | 
| EPS Basic | -0.27 | -0.27 | -0.29 | -0.31 | -0.32 | 
| Normalized Basic EPS | -0.17 | -0.17 | -0.18 | -0.19 | -0.20 | 
| EPS Diluted | -0.27 | -0.27 | -0.29 | -0.31 | -0.32 | 
| Normalized Diluted EPS | -0.17 | -0.17 | -0.18 | -0.19 | -0.20 | 
| Average Basic Shares Outstanding | 135.52M | 120.37M | 105.22M | 103.59M | 103.29M | 
| Average Diluted Shares Outstanding | 135.52M | 120.37M | 105.22M | 103.59M | 103.29M | 
| Dividend Per Share | -- | -- | -- | -- | -- | 
| Payout Ratio | -- | -- | -- | -- | -- |